Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fierce Health vs NowPatient

Fierce Health
Graded #411

Lower grade

vs+8.899999999999999
NowPatient
Graded #222

Higher grade

The verdict

NowPatient takes it — 65.5/100 to 56.6/100.

NowPatient grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NowPatient is a US-UK telehealth platform offering brand-name GLP-1 weight management access including Mounjaro, Wegovy (injection and oral tablet), and Saxenda.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNowPatient +2
33
35
Dose & formulationNowPatient +16
77
93
Clinical oversightNowPatient +24
62
86
Labs & monitoringNowPatient +2
52
54
FulfillmentFierce Health +5
75
70
Contract termsNowPatient +8
47
55
Fierce Health · left barNowPatient · right bar

The numbers

MetricFierce HealthNowPatient
WeighScore56.6/10065.5/100
GradeCC
Scorecard rank#411#222
Semaglutide$297/mo (3-month plan, compounded)$1,349/mo (brand Wegovy)
Tirzepatide$497/mo (3-month plan, compounded)$1,069/mo (brand Mounjaro, promotional rate)
Coverage30 statesCoverage not published
Brand-name accessYesYes
Oral / sublingualInjection onlyYes
Fierce Health

Graded #411 · C

Strengths

  • 30-state service list spelled out in the Terms — buyers can verify eligibility before intake
  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer on every product page
  • Four GLP-1 programs (standard and microdose semaglutide and tirzepatide) — a broader ladder than peers
  • Microdose tier at $197/mo is one of the lower entry points we've seen

Where it loses points

  • No named 503A compounding pharmacy partner — only generic 'partner pharmacies' language
  • Operating LLC name not disclosed anywhere on the site
  • Tirzepatide weight-loss program ($497/mo) showing 'sold out or unavailable' across all plans at review time
  • Clinical provider network not named
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
NowPatient

Graded #222 · C

Strengths

  • Free telehealth consultation — you only pay for the medication
  • Brand-name Mounjaro, Wegovy injection, Wegovy oral tablet, and Saxenda all available
  • One of the few platforms offering Wegovy in both injection and oral pill form
  • No compounded options — every drug is FDA-approved brand-name

Where it loses points

  • Cash-pay pricing tracks full brand list price (~$1,000–$1,350/mo)
  • No compounded semaglutide or tirzepatide (usually the cheaper route)
  • State availability determined during intake, not shown upfront
  • Does not offer Foundayo (orforglipron)

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard